# Sault Area Hospital January - December 2024 Antibiogram report

## All Location Non-Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Levofloxacin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | *Pseudomonas aeruginosa* | 234 | | | | | 85 | | 85 | | | 94 | 98 | | | | 76 | 65 | | 99 | | | | |
| | *Escherichia coli* | 125 | 49 | 73 | | | 81 | 100 | 100 | 23 | 84 | 84 | | | | 80 | 65 | | 87 | 94 | 99 | 82 | | |
| | *Klebsiella pneumoniae* | 33 | 0 | 94 | | | 94 | 100 | 100 | 42 | 92 | 92 | | | | 100 | 94 | | 96 | 93 | 100 | 96 | | |
| | *Enterobacter cloacae complex* | 21 | 0 | 0 | | | 0 | 90 | 100 | 0 | | | | | | 90 | 69 | | 94 | 93 | 100 | 88 | | |
| | *Stenotrophomonas maltophilia* | 21 | | | | | | | | | | | | | | 71 | | 68 | | | | | | |
| | *Serratia marcescens* | 13 | 0 | 0 | | | 0 | 100 | 100 | 0 | | | | | | 100 | 71 | | 100 | 100 | 100 | 50 | | |
| | *Proteus mirabilis* | 12 | 75 | 75 | | | 100 | 100 | 100 | 40 | 100 | 100 | | | | 75 | 79 | | 83 | 100 | 100 | 0 | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | Staphyloccocus aureus,all isolates | 745 | | | | 73 | 73 | 73 | 73 | 73 | | | | 82 | 67 | 98 | 71 | | | | | 96 | 100 | 100 |
| | -methicillin-susceptible | 543 | | | | 100 | 100 | 100 | 100 | 100 | | | | 82 | 77 | 98 | 86 | | | | | 97 | 100 | 100 |
| | - *methicillin-resistant (MRSA)* | 202 | | | | 0 | 0 | 0 | 0 | 0 | | | | 81 | 39 | 98 | 32 | | | | | 95 | 100 | 100 |
| | Group B streptococci | 150 | | | 100 | | | | | | | | | 63 | 59 | | | | | | | | 100 | |
| | Group A streptococci | 146 | | | 100 | | | | | | | | | 74 | 75 | | | | | | | | 100 | |
| | Coagulase-negative staphylococci | 83 | | | | 39 | 39 | 39 | 39 | 39 | | | | 61 | 40 | 54 | 57 | | | | | 89 | 100 | |
| | Group G streptococci | 57 | | | 100 | | | | | | | | | 88 | 88 | | | | | | | | 100 | |
| | *Streptococcus pneumoniae* | 52 | | | 100 | | | | | | | | | 98 | 90 | 83 | | 100 | | | | 59 | 100 | |
| | *Enterococcus faecalis* | 45 | 100 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | 100 | 100 |
| | Group C streptococci | 25 | | | 100 | | | | | | | | | 80 | 80 | | | | | | | | 100 | |
| | *Streptococcus anginososus group* | 21 | | | 100 | | | | | | | | | 93 | 93 | | | | | | | | 100 | |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Levofloxacin susceptibility results based on testing from respiratory isolates only
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital January - December 2024 Antibiogram report

## All Locations Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cephalexin | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Nitrofurantoin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Escherichia coli* | 855 | 57 | 80 | | | 85 | 100 | 100 | 87 | 87 | 88 | 88 | | | | 79 | 62 | 96 | 93 | 92 | 99 | 82 | | |
| | *Klebsiella pneumoniae* | 255 | 0 | 91 | | | 90 | 100 | 100 | 94 | 93 | 100 | 100 | | | | 95 | 77 | 21 | 99 | 99 | 100 | 86 | | |
| | *Pseudomonas aeruginosa* | 171 | | | | | 96 | | 98 | | | | 96 | 98 | | | | 84 | | | 98 | 99 | | | |
| | *Proteus mirabilis* | 110 | 76 | 83 | | | 100 | 100 | 100 | 98 | 98 | 99 | 99 | | | | 90 | 55 | 0 | 88 | 95 | 100 | 0 | | |
| | *Enterobacter cloacae complex* | 81 | 0 | 0 | | | 0 | 96 | 100 | | 0 | | | | | | 89 | 78 | 35 | 98 | 95 | 100 | 88 | | |
| | *Klebsiella oxytoca* | 66 | 0 | 90 | | | 90 | 98 | 98 | | 78 | 88 | 88 | | | | 96 | 89 | 82 | 98 | 98 | 100 | 97 | | |
| | *Citrobacter freundii complex* | 42 | 0 | 0 | | | 0 | 98 | 98 | | 0 | | | | | | 85 | 60 | 89 | 88 | 96 | 100 | 88 | | |
| | *Serratia marcescens* | 29 | 0 | 0 | | | 0 | 100 | 100 | | 0 | | | | | | 93 | 53 | 0 | 96 | 100 | 100 | 15 | | |
| | *Providencia rettgeri* | 20 | 0 | 0 | | | 0 | 100 | 100 | | 0 | | | | | | 100 | 86 | 0 | 88 | 93 | 100 | 0 | | |
| | *Morganella morganii* | 18 | 0 | 0 | | | 0 | 100 | 100 | | 0 | | | | | | 94 | 89 | 0 | 100 | 100 | 100 | 0 | | |
| | *Klebsiella (Enterobacter) aerogenes* | 15 | 0 | 0 | | | 0 | 91 | 100 | | 0 | | | | | | 100 | 92 | 17 | 100 | 100 | 100 | 92 | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Enterococcus faecalis* | 227 | 100 | 100 | 100 | | 100 | | | | | | | | | | | 75 | 100 | | | | 24 | 98 | 100 |
| | Coagulase-negative staphylococci | 124 | | | | 44 | 44 | 44 | 44 | | 44 | | | | | | 55 | 33 | 100 | | | | 91 | 100 | |
| | Staphyloccocus aureus,all isolates | 70 | | | | 61 | 61 | 61 | 61 | | 61 | | | | | | 100 | 49 | 100 | | | | 93 | 100 | |
| | -methicillin-susceptible | 43 | | | | 100 | 100 | 100 | 100 | | 100 | | | | | | 100 | 79 | 100 | | | | 98 | 100 | |
| | - *methicillin-resistant (MRSA)* | 27 | | | | 0 | 0 | 0 | 0 | | 0 | | | | | | 100 | 0 | 100 | | | | 85 | 100 | |
| | *Enterococcus faecium* | 31 | 13 | 13 | 13 | | 13 | | | | | | | | | | | 9 | 13 | | | | 9 | 78 | |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital January - December 2024 Antibiogram report

## In-Patient Non-Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Levofloxacin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | *Pseudomonas aeruginosa* | 83 | | | | | 78 | | 71 | | | 93 | 100 | | | | 72 | 53 | | 97 | | | | |
| | *Escherichia coli* | 24 | 38 | 71 | | | 75 | 100 | 100 | 14 | 80 | 80 | | | | 79 | 54 | | 95 | 100 | 100 | 90 | | |
| | *Stenotrophomonas maltophilia* | 15 | | | | | | | | | | | | | | 67 | | 57 | | | | | | |
| | *Enterobacter cloacae cplx* | 10 | 0 | 0 | | | 0 | 89 | 100 | 0 | | | | | | 80 | 67 | | 89 | 88 | 100 | 88 | | |
| | *Klebsiella pneumoniae* | 10 | 0 | 100 | | | 100 | 100 | 100 | 33 | | | | | | 100 | 93 | | 100 | 100 | 100 | 100 | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | Staphyloccocus aureus,all isolates | 117 | | | | 74 | 74 | 74 | 74 | 74 | | | | 75 | 58 | 96 | 67 | | | | | 99 | 100 | |
| | -methicillin-susceptible | 86 | | | | 100 | 100 | 100 | 100 | 100 | | | | 77 | 75 | 95 | 87 | | | | | 98 | 100 | |
| | - *methicillin-resistant (MRSA)* | 31 | | | | 0 | 0 | 0 | 0 | 0 | | | | 71 | 10 | 97 | 10 | | | | | 100 | 100 | 100 |
| | Coagulase-negative staphylococci | 53 | | | | 29 | 29 | 29 | 29 | 29 | | | | 55 | 36 | 44 | 48 | | | | | 88 | 100 | |
| | *Enterococcus faecalis* | 17 | 100 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | 100 | 100 |
| | Group B streptococci | 14 | | | 100 | | | | | | | | | 50 | 50 | | | | | | | | 100 | |
| | Group A streptococci | 13 | | | 100 | | | | | | | | | 85 | 85 | | | | | | | | 100 | |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Levofloxacin susceptibility results based on testing from respiratory isolates only
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital January - December 2024 Antibiogram report

## In-Patient Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cephalexin | IV Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Nitrofurantoin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Escherichia coli* | 169 | 62 | 83 | | | 87 | 100 | 100 | 91 | 91 | 91 | 91 | | | | 82 | 67 | 96 | 92 | 92 | 100 | 85 | | |
| | *Klebsiella pneumoniae* | 75 | 0 | 88 | | | 88 | 100 | 100 | 91 | 91 | 88 | 88 | | | | 94 | 79 | 23 | 100 | 94 | 100 | 88 | | |
| | *Pseudomonas aeruginosa* | 42 | | | | | 86 | | 93 | | | | 88 | 100 | | | | 90 | | | 98 | 100 | | | |
| | *Proteus mirabilis* | 27 | 78 | 82 | | | 100 | 100 | 100 | 100 | 100 | 100 | 100 | | | | 96 | 70 | 0 | 88 | 96 | 100 | 0 | | |
| | *Enterobacter cloacae complex* | 23 | 0 | 0 | | | 0 | 91 | 100 | | 0 | | | | | | 83 | 100 | 43 | 93 | 100 | 100 | 100 | | |
| | *Klebsiella oxytoca* | 17 | 0 | 81 | | | 87 | 94 | 94 | | 84 | 81 | 81 | | | | 94 | 70 | 88 | 100 | 94 | 100 | 100 | | |
| | *Serratia marcecens* | 15 | 0 | 0 | | | 0 | 100 | 100 | | 0 | | | | | | 85 | 47 | 0 | 92 | 100 | 100 | 18 | | |
| | *Citrobacter species* | 14 | 0 | 0 | | | 0 | 93 | 93 | | 0 | | | | | | 77 | 73 | 77 | 84 | 100 | 100 | 85 | | |
| 0 | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Enterococcus faecalis* | 82 | 100 | 100 | 100 | | 100 | | | | | | | | | | | 73 | 100 | | | | 85 | 100 | 100 |
| | Coagulase-negative staphylococci | 29 | | | | 31 | 31 | 31 | 31 | | 31 | | | | | | 38 | 28 | 100 | | | | 93 | 100 | |
| | *Enterococcus faecium* | 17 | 12 | 12 | 12 | | 12 | | | | | | | | | | | 13 | 0 | | | | 12 | 100 | 100 |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital January - December 2024 Antibiogram report

## ED Non-Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Levofloxacin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | *Escherichia coli* | 95 | 53 | 75 | | | 83 | 100 | 100 | 25 | 85 | 85 | | | | 82 | 67 | | 88 | 92 | 99 | 82 | | |
| | *Pseudomonas aeruginosa* | 70 | | | | | 85 | | 91 | | | 91 | 97 | | | | 70 | 67 | | 100 | | | | |
| | *Klebsiella pneumoniae* | 20 | 0 | 95 | | | 95 | 100 | 100 | 45 | 94 | 94 | | | | 100 | 93 | | 94 | 89 | 100 | 94 | | |
| | *Proteus mirabilis* | 10 | 80 | 80 | | | 100 | 100 | 100 | 41 | 100 | 100 | | | | 70 | 76 | | 80 | 100 | 100 | 0 | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | Staphyloccocus aureus,all isolates | 437 | | | | 70 | 70 | 70 | 70 | 70 | | | | 86 | 69 | 97 | 72 | | | | | 97 | 100 | |
| | -methicillin-susceptible | 307 | | | | 100 | 100 | 100 | 100 | 100 | | | | 84 | 78 | 97 | 85 | | | | | 98 | 100 | |
| | - *methicillin-resistant (MRSA)* | 130 | | | | 0 | 0 | 0 | 0 | 0 | | | | 92 | 48 | 98 | 41 | | | | | 95 | 100 | 100 |
| | Group A streptococci | 122 | | | 100 | | | | | | | | | 72 | 73 | | | | | | | | 100 | |
| | Group G streptococci | 44 | | | 100 | | | | | | | | | 89 | 89 | | | | | | | | 100 | |
| | *Streptococcus pneumoniae* | 42 | | | 100 | | | | | | | | | 98 | 90 | 83 | | 100 | | | | 54 | 100 | |
| | Group B streptococci | 37 | | | 100 | | | | | | | | | 59 | 57 | | | | | | | | 100 | |
| | Coagulase-negative staphylococci | 21 | | | | 62 | 62 | 62 | 62 | 62 | | | | 67 | 48 | 67 | 71 | | | | | 85 | 100 | |
| | *Enterococcus faecalis* | 14 | 100 | 100 | 100 | | 100 | | | | | | | | | | | | | | | | 100 | 100 |
| | Group C streptococci | 13 | | | 100 | | | | | | | | | 85 | 85 | | | | | | | | 100 | |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Levofloxacin susceptibility results based on testing from respiratory isolates only
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital January - December 2024 Antibiogram report

## ED Urine Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cephalexin | IV Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Nitrofurantoin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Escherichia coli* | 455 | 56 | 80 | | | 85 | 100 | 100 | 87 | 88 | 89 | 89 | | | | 79 | 68 | 98 | 93 | 93 | 100 | 82 | | |
| | *Klebsiella pneumoniae* | 101 | 0 | 89 | | | 90 | 100 | 100 | 94 | 94 | 96 | 96 | | | | 97 | 80 | 21 | 89 | 98 | 100 | 89 | | |
| | *Pseudomonas aeruginosa* | 61 | | | | | 88 | | 96 | | | | 98 | 98 | | | | 80 | | | 100 | 100 | | | |
| | *Proteus mirabilis* | 40 | 85 | 83 | | | 100 | 100 | 100 | 97 | 98 | 100 | 100 | | | | 95 | 73 | 0 | 95 | 92 | 100 | 0 | | |
| | *Enterobacter cloacae complex* | 23 | 0 | 0 | | | 0 | 100 | 100 | | 0 | 0 | 0 | | | | 88 | 88 | 50 | 100 | 88 | 100 | 88 | | |
| | *Klebsiella oxytoca* | 20 | 0 | 95 | | | 100 | 100 | 100 | | 76 | 100 | 100 | | | | 100 | 100 | 80 | 100 | 100 | 100 | 95 | | |
| | *Citrobacter freundii complex* | 16 | 0 | 0 | | | 0 | 100 | 100 | | 0 | 0 | 0 | | | | 74 | 55 | 94 | 74 | 93 | 100 | 81 | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | | |
| | *Enterococcus faecalis* | 51 | 100 | 100 | 100 | | 100 | | | | | | | | | | | 75 | 100 | | | | 24 | 100 | 100 |
| | *Coagulase-negative staphylococci* | 31 | | | | 45 | 45 | 45 | 45 | 45 | 45 | | | | | | 61 | 48 | 100 | ` | | | 83 | 100 | |
| | Staphyloccocus aureus,all isolates | 28 | | | | 64 | 64 | 64 | 64 | 64 | 64 | | | | | | 100 | 50 | 100 | | | | 85 | 100 | |
| | -methicillin-susceptible | 18 | | | | 100 | 100 | 100 | 100 | 100 | 100 | | | | | | 100 | 78 | 100 | | | | 94 | 100 | |
| | - *methicillin-resistant (MRSA)* | 10 | | | | 0 | 0 | 0 | 0 | 0 | 0 | | | | | | 100 | 0 | 100 | | | | 70 | 100 | |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital 2024 Antibiogram report

## ICU Non-Urine Isolates — % Susceptible

| | ≥80% Susceptible<br>70-79% Susceptible<br>≤69% Susceptible<br>Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Levofloxacin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | |
| | *Pseudomonas aeruginosa* | 20 | | | | | 74 | | 67 | | | 85 | 100 | | | | 76 | 63 | 89 | | | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | |
| | Staphyloccocus aureus,all isolates | 27 | | | | 85 | 85 | 85 | 85 | 85 | | | | 82 | 71 | 100 | 73 | | | | 100 | 100 | 100 |
| | -methicillin-susceptible | 23 | | | | 100 | 100 | 100 | 100 | 100 | | | | 87 | 83 | 100 | 86 | | | | 100 | 100 | 100 |
| | - *methicillin-resistant (MRSA)* | 4 | | | | 0 | 0 | 0 | 0 | 0 | | | | 50 | 0 | 100 | 0 | | | | 100 | 100 | 100 |
| | *Coagulase-negative staphylococci* | 11 | | | | 20 | 20 | 20 | 20 | 20 | | | | 27 | 27 | 27 | 14 | | | | 90 | 100 | 100 |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Levofloxacin susceptibility results based on testing from respiratory isolates only
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

# Sault Area Hospital 2024 Antibiogram report

## All Locations Blood Isolates — % Susceptible

≥80% Susceptible
70-79% Susceptible
≤69% Susceptible

| | Organism | # of isolates | Ampicillin | Amoxicillin-Clavulanic Acid | Penicillin | Cloxacillin | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Ceftriaxone | Ceftazidime | Ceftolozane-Tazobactam | Clindamycin | Erythromycin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Levofloxacin | Gentamicin | Tobramycin | Amikacin | Doxycycline | Vancomycin | Linezolid |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | *Escherichia coli* | 102 | 50 | 73 | | | 81 | 100 | 100 | 23 | 83 | 83 | | | | 81 | 65 | | 89 | 93 | 99 | 85 | | |
| | *Klebsiella pneumoniae* | 23 | 0 | 91 | | | 91 | 100 | 100 | 45 | 88 | 88 | | | | 100 | 92 | | 95 | 89 | 100 | 94 | | |
| | *Pseudomonas aeruginosa* | 10 | | | | | 67 | | 100 | | | 100 | 100 | | | | 67 | | | 100 | | | | |
| Gram-Positive | **GRAM-POSITIVE ORGANISMS** | | | | | | | | | | | | | | | | | | | | | | | |
| | Staphyloccocus aureus,all isolates | 58 | | | | 72 | 72 | 72 | 72 | 72 | | | | 88 | 76 | 87 | 81 | | | | | 100 | 100 | 100 |
| | -methicillin-susceptible | 42 | | | | 100 | 100 | 100 | 100 | 100 | | | | 86 | 83 | 85 | 91 | | | | | 100 | 100 | 100 |
| | - *methicillin-resistant (MRSA)* | 16 | | | | 0 | 0 | 0 | 0 | 0 | | | | 94 | 56 | 89 | 55 | | | | | 100 | 100 | 100 |
| | *Coagulase-negative staphylococci* | 34 | | | | 45 | 45 | 45 | 45 | 45 | | | | 60 | 43 | 46 | 50 | | | | | 86 | 100 | |
| | *Streptococcus pneumoniae* | 33 | | | 100 | | | | | | | | | 100 | 94 | 79 | | 100 | | | | 44 | 100 | |
| | *Enterococcus faecalis* | 21 | | | 100 | | | | | | | | | | | | | | | | | | 100 | 100 |
| | *Group A streptococci* | 15 | 100 | 100 | 100 | | 100 | | | | | | | 80 | 87 | | | | | | | | 100 | |
| | *Group G streptococci* | 13 | 100 | 100 | 100 | | 100 | | | | | | | 85 | 85 | | | | | | | | 100 | |
| | *Group B streptococci* | 10 | 100 | 100 | 100 | | 100 | | | | | | | 70 | 70 | | | | | | | | 100 | |

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited.
- Some organisms for which there were only very small numbers have been excluded
- Patient duplicates excluded
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25

## Sault Area Hospital January - December 2024 Antibiogram report

### Blood Isolates ALL Patients — % Susceptible

| Organism | # of isolates | Fluconazole | Voriconazole | Caspofungin | Micafungin | Anidulafungin |
|---|---|---|---|---|---|---|
| **ALL Candida** | 13 | | | | | |
| *Candida albicans** | 9 | | | | | |
| *Candida glabrata*** | 2 | 100 | | 100 | 100 | 100 |
| *Candida lipolytica**** | 1 | | | | | |
| *Candida tropicalis* | 1 | 100 | 100 | 100 | 100 | 100 |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.

- Patient duplicates excluded
- **Candida albicans* : Routine susceptibility testing for this isolate was temporarity suspended by PHL. Isolate generally susceptible to all agents.
- ***Candida glabrata* : There are no interpretative breakpoints for voriconazole. There are no susceptibility breakpoints for fluconazole, the percentage provided refers to the percentage of Candida glabrata that are susceptible dose-dependent.
- ****Candida lipolytica* : There are no interpretative breakpoints for *this organism*

## Sault Area Hospital 2024 ESBL Data

| Location | Source | ESBL Rate | # Isolates |
|---|---|---|---|
| Facility | Non-Urine | 5% | 133 |
| In-Patient | Non-Urine | 14% | 34 |
| ED | Non-Urine | 12% | 123 |
| | | | |
| Facility | Urine | 9% | 1219 |
| In-Patient | Urine | 7% | 270 |
| ED | Urine | 9% | 596 |

# Sault Area Hospital January - December 2024 Antibiogram report

## All Locations -All Sources - All SPICE / AmpC Isolates — % Susceptible

| | ≥80% Susceptible<br>70-79% Susceptible<br>≤69% Susceptible<br>Organism | # of isolates | % | Ampicillin | Amoxicillin-Clavulanic Acid | Piperacillin-Tazobactam | Ertapenem | Meropenem | Cefazolin | Trimethoprim-Sulfamethoxazole | Ciprofloxacin | Gentamicin | Tobramycin | Amikacin | Doxycycline |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gram-Negative | **GRAM-NEGATIVE ORGANISMS** | | | | | | | | | | | | | | |
| | *Enterobacter cloacae complex* | 102 | | 0 | 0 | 0 | 95 | 100 | 0 | 89 | 76 | 98 | 95 | 100 | 88 |
| | *Citrobacter freundii complex* | 49 | | 0 | 0 | 0 | 95 | 98 | 0 | 86 | 64 | 87 | 98 | 100 | 86 |
| | *Serratia marcenscens* | 42 | | 0 | 0 | 0 | 100 | 100 | 0 | 95 | 58 | 97 | 100 | 100 | 25 |
| | *Morganella morganii* | 20 | | 0 | 0 | 0 | 100 | 100 | 0 | 95 | 85 | 100 | 100 | 100 | 0 |
| | *Providencia rettgeri* | 20 | | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 86 | 88 | 93 | 100 | 0 |
| | *Klebsiella (Enterobacter) aerogenes* | 19 | | 0 | 0 | 0 | 95 | 100 | 0 | 96 | 91 | 100 | 100 | 100 | 95 |
| | *Citrobacter koseri* | 13 | | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 86 | 100 | 100 | 100 | 100 |
| | *Hafnia species* | 6 | | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 79 |
| | *Pantoea species* | 5 | | 0 | 0 | 0 | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 |

**General Notes:**

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30
- Patient duplicates excluded
- Susceptibility to doxycycline was predicted based on tetracycline susceptibility testing results.

Prepared by Senior Technologist Microbiology

Jul-25